Investor Presentaiton

Investor Presentation First six months of 2018. Slide 102 VictozaⓇ accounts for 22% of total sales in first six months of 2018 Reported currencies Sales Q2 2018 (mDKK) Sales split Sales full H1 2018 (mDKK) Sales split TresibaⓇ 1,952 7% 3,707 7% LevemirⓇ 3,023 11% 5,803 11% NovoRapidⓇ 4,799 18% 9,494 17% NovoMix® 2,408 9% 4,909 9% VictozaⓇ 5,729 21% 11,718 22% OzempicⓇ 195 1% 264 0% SaxendaⓇ 883 3% 1,653 3% Diabetes care and Obesity¹ 23,033 84% 45,641 84% NovoSevenⓇ 1,886 7% 4,040 7% NorditropinⓇ 1,703 6% 3,184 6% Biopharmaceuticals¹ 4,374 16% 8,696 16% Total¹ 27,407 100% 54,337 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed changing diabetes® novo nordisk

View entire presentation